Functions of a GyrBA fusion protein and its interaction with QnrB and quinolones

Antimicrobial Agents and Chemotherapy
Chunhui ChenDavid C Hooper

Abstract

In order to study the interactions between Escherichia coli DNA gyrase and the gyrase interacting protein QnrB in vivo, we constructed a gyrB-gyrA fusion and validated its ability to correct the temperature-sensitive growth of gyrA and gyrB mutants. Like wild-type gyrA, the gyrB-gyrA fusion complemented a quinolone-resistant gyrA mutant to increase susceptibility. It functioned as an active type II topoisomerase, catalyzed negative supercoiling of DNA, was inhibited by quinolone, and was protected by QnrB.

References

Nov 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·M GellertH A Nash
Apr 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·N P HigginsN R Cozzarelli
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·H YoshidaS Nakamura
Jul 18, 2001·Biochemistry·L S Lavasani, H Hiasa
Mar 29, 2002·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Sonia Trigueros, Joaquim Roca
Apr 12, 2002·Proceedings of the National Academy of Sciences of the United States of America·John H Tran, George A Jacoby
Feb 1, 2003·Current Drug Targets·P G HigginsF J Schmitz
Dec 24, 2004·Antimicrobial Agents and Chemotherapy·John H TranDavid C Hooper
May 21, 2011·The Journal of Biological Chemistry·Matthew W VettingJohn S Blanchard
Aug 6, 2011·Proceedings of the National Academy of Sciences of the United States of America·Airat Gubaev, Dagmar Klostermeier
Feb 11, 2014·Journal of Bacteriology·Regis A VilletDavid C Hooper

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.